Evidence map›Paper›PMID 40660492›Full record

ArticleBioanalysis2025

Impact of drug concentration and ADA assay drug tolerance on the assessment and correlation of titer and signal to noise.

Lili Guo, Kevin Carleton, Yong Jiang, Christopher Ehlinger

Abstract read
In one paragraph

Article in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lili GuoBioanalytical Discovery and Development Sciences, Johnson & Johnson, Spring House, PA, USA.
Kevin CarletonBioanalytical Discovery and Development Sciences, Johnson & Johnson, Spring House, PA, USA.
Yong JiangBioanalytical Discovery and Development Sciences, Johnson & Johnson, Spring House, PA, USA.
Christopher EhlingerBioanalytical Discovery and Development Sciences, Johnson & Johnson, Spring House, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe three-tiered testing strategy for an anti-drug antibody (ADA) assay is a common practice for assessing the immunogenicity to therapeutic products. Efforts to streamline the ADA testing process led to proposals of using signal to noise ( METHOD/

resultExperimental and clinical ADA datasets were examined to assess how drug concentration and the assay drug tolerance affect the measurement and correlation of

conclusionThe presence of drug in clinical samples and the drug tolerance of the ADA assay simultaneously influence the measurement and correlation of

Indexed as

Adenosine DeaminaseAntibodiesDrug ToleranceHumansPharmaceutical PreparationsSignal-To-Noise RatioAdenosine DeaminaseAntibodiesPharmaceutical Preparationsanti-drug antibody (ADA)drug concentrationdrug tolerancefold differenceimmunogenicitySignal to noise (S/N)titer

Identifiers

PMID40660492
PMCPMC12367090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.